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Introduction: Systemic sclerosis (SSc) is a complex and not fully understood autoimmune disease associated with
fibrosis of multiple organs. The main effector cells, the myofibroblasts, are collagen-producing cells derived from
the activation of resting fibroblasts. This process is regulated by a complex repertoire of profibrotic cytokines, and
among them transforming growth factor beta (TGF-β) and endothelin-1 (ET-1) play a major role. In this paper we
show that TGF-β and ET-1 receptors co-operate in myofibroblast activation, and macitentan, an ET-1 receptor
antagonist binding ET-1 receptors, might interfere with both TGF-β and ET-1 pathways, preventing myofibroblast
differentiation.
Methods: Fibroblasts isolated from healthy controls and SSc patients were treated with TGF-β and ET-1 and
successively analyzed for alpha smooth muscle actin (α-SMA) and collagen (Col1A1) expression and for the Sma
and Mad Related (SMAD) phosphorylation. We further tested the ability of macitentan to interfere with these
process. Furthermore, we silenced ET-1 and endothelin-1 receptor A expression and evaluated the formation of an
ET-1/TGF-β receptor complex by immunoprecitation assay.
Results: We showed myofibroblast activation in SSc fibroblasts assessing the expression of α-SMA and Col1A1, after
stimulation with TGF-β and ET-1. Macitentan interfered with both ET-1- and TGF-β-induced fibroblast activation. To
explain this unexpected inhibitory effect of macitentan on TGF-β activity, we silenced ET-1 expression on SSc
fibroblasts and co-immunoprecipitated these two receptors, showing the formation of an ET-1/TGF-β receptor
complex.
Conclusions: During SSc, ET-1 produced by activated endothelia contributes to myofibroblast activation using TGF-β
machinery via an ET-1/TGF-β receptor complex. Macitentan interferes with the profibrotic action of TGF-β, blocking the
ET-1 receptor portion of the ET-1/TGF-β receptor complex.* Correspondence: paola.cipriani@cc.univaq.it
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Systemic sclerosis (SSc) is characterized as an immune
dysregulation and vascular injury that generally precedes
and contributes to the development of fibrosis. During
the disease, the tightly regulated and self-limited re-
sponse to injury that normally leads to tissue regener-
ation is subverted into fibrosis, with disruption of tissue
architecture and loss of functional integrity. Once
started, fibroblast (FB) activation, leading to collagen
and alpha smooth muscle actin (α-SMA) upregulation, is
amplified through multiple feedforward loops, generated
as a consequence of tissue damage, as well as hypoxia
and oxidative stress [1]. Although the pathophysiological
mechanisms of SSc fibrosis is still largely unknown, in-
jured endothelial cells (ECs) and pericytes may play an
pivotal role in this process due to their ability to trans-
differentiate toward activated myofibroblasts [2–4], pro-
ducing increased amounts of collagen [5–7]. In this
setting, both endothelin-1 (ET-1) and transforming
growth factor beta (TGF-β) have been shown to play a
key role in this process. ET-1, one of the three members
of ET family, is known to have a strong vasoconstrictive
activity and is further involved in vascular remodeling.
The molecule is largely released from ECs [8, 9] and
binds two different receptors, endothelin-1 receptor A
and B (ETAR and ETBR) [10]. ET-1 is involved in SSc
vasculopathy, including digital ulcers and pulmonary
arterial hypertension (PAH) [11, 12], and its targeting
represents an important therapy for these vascular mani-
festations. Recently, ET-1 has been implicated in the fi-
brotic process in different organs, such as skin, lung and
heart [13, 14], although the detailed mechanism of the
ET-1 effects still needs to be clarified.
TGF-β is the main profibrotic cytokine involved in the
pathogenesis of fibrosis in SSc, inducing FB activation,
collagen production and subsequent remodeling of the
extracellular matrix (ECM) [15]. TGF-β, after binding
with specific receptors, induces the formation of a type
II–type I receptor complex, in which the constitutively
active type II receptor (TβRII) phosphorylates and acti-
vates the type I receptor (TβRI). Successively, the signal
is transduced to the nucleus by members of the Sma and
Mad Related (SMAD) family. In the past years, the in-
duction of SMAD1/5 phosphorylation by TGF-β was
considered to be specific to ECs [16, 17], although it has
been recently shown that TGF-β may induce phosphoryl-
ation of both SMAD1 and SMAD5, together with phos-
phorylation of SMAD2/3, in different cell lines, such as
epithelial cells, FBs and cancer-derived cell lines [18].
It has been recently suggested that TGF-β, although
highly activated, may be not sufficient to support the
persistent fibrotic responses noted in SSc patients [19],
but that it is working in synergy with other extracellular
ligands, such as connective tissue growth factor andET-1 [19]. Over the past years, different groups [15, 20]
have pointed out roles for TGF-β and ET-1 on the FB
acquisition of phenotype and function associated with
myofibroblasts.
In this work, we provide evidence that macitentan
(MAC), a novel specific ETAR/ETBR antagonist [21],
prevents SSc FB activation induced by TGF-β, blocking
protein collagen 1 alpha 1 (Col1A1) production and α-
SMA expression. We further show that its inhibitory ef-
fect is due to the presence on the FB surface of a func-
tional endothelin receptor (ETR)/TβRI complex, whose
ETR portion is recognized and blocked by MAC.
Understanding the mechanism regulating ET-1/TGF-β
receptor interaction, may provide new future possibilities
in the treatment of fibrosis, a situation still needing ef-
fective therapies.Methods
Patients and FB isolation
After approval from the San Salvatore University Hospital
ethics committee and written informed consent from pa-
tients, FBs were obtained from 10 SSc patients with the
diffuse form of disease of recent onset (disease duration
less than 3 years calculated since the first nonRaynaud’s
symptom of SSc) [22, 23] by skin biopsies. Demographic
and clinical characteristics of the patients are shown in
Table 1.
Patients discontinued corticosteroids, oral vasodilators,
intravenous prostanoids or other potentially disease-
modifying drugs at least 1 month before biopsies. None
received immunosuppressants.
Frozen FB samples obtained from age-matched healthy
women donors of skin samples, for research purposes,
were used as controls.
Biopsy samples (1 × 0.5 cm) of the involved forearm
skin (skin score 1/2 at the biopsy site) were washed with
phosphate-buffered saline (Life Technologies, CA, USA)
and four explants were placed into a 50 ml tube contain-
ing 15 ml collagenase (Sigma-Aldrich, MO, USA) and
then digested for 2 h at 37 °C. Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; GIBCO,
CA, USA), supplemented with 10 % fetal bovine serum
(Standard South America origin, Lonza, MD, USA), 2
mmol/l L-glutamine (EuroClone, Milan, Italy), and 100
U Penicillin and 1,000 U Streptomycin (Biochrom AG,
FL, USA). At 80 % confluence the FBs were split and
subcultured. Third-passage (P3) FBs were analyzed for
the surface expression of S100A4.FBs treatment with TGF-β, ET-1 and MAC
To establish the optimal concentration of TGF-β (R&D,
USA), ET-1 (Sigma-Aldrich) and MAC in our system, a
dose–response curve was performed on α-SMA expression
Table 1 Clinical and demographic features of the 10 diffuse systemic sclerosis patients
Sex/age
(years)
Year of SSc onset/disease











F/46 2010/2 12/2 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2009/3 13/1 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/31 2011/1 13/2 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes
F/36 2010/2 11/2 ANA/Scl-70 Normal/Normal PAH/No Yes/Yes
M/20 2010/2 11/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/41 2010/2 15/2 ANA/Scl-70 Normal/Normal Normal/No No/No
F/30 2010/2 10/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/21 2010/2 09/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/31 2009/3 14/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No
F/42 2009/3 16/2 ANA/Scl-70 Fibrosis/Normal Normal/No Yes/No
The internal organ involvement refers to the time of biopsy. ANA antinuclear antibodies, F female, HRCT high-resolution computed tomography, M male, MRSS
modified Rodnan skin thickness score (maximum possible score 51), PAH pulmonary arterial hypertension, PFT pulmonary function test, Scl-70 anti-topoisomerase,
SSc systemic sclerosis
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control and one patient.
Each experiment was performed in triplicate, and the
optimal stimulation dose for TGF-β was assessed to be
10 ng/ml, for ET-1 it was assessed to be 200 nM, and for
MAC, 1 μM.
To assess α-SMA and Col1A1 expression, FBs were
treated under the following conditions: 1) untreated (UT)
FBs; 2) FBs + TGF-β (10 ng/ml); 3) FBs pretreated (1 h)
with MAC (1 μM), before being treated with TGF-β; 4)
FBs + ET-1 (200nM); 5) FBs pretreated (1 h) with MAC (1
μM), before being treated with ET-1. The experimental
conditions were applied for 6 days in DMEM with 1 %
fetal bovine serum and the medium was changed every 2
days.
To assess SMAD1/5, SMAD2/3 phosphorylation and
immunoprecipitation experiments, FBs were treated
under the following conditions: 1) UT FBs; 2) FBs +
TGF-β (10 ng/ml); 3) FBs pretreated (1 h) with MAC
(1 μM), before being treated with TGF-β; 4) FBs + ET-1
(200nM); 5) FBs pretreated (1 h) with MAC (1 μM),
before being treated with ET-1. The experimental con-
ditions were applied for 24 h in DMEM with 1 % fetal
bovine serum.
Western blot
In order to perform Western blot assays, FBs cells were
pelleted, washed twice with phosphate-buffered saline,
lysed in lysis buffer (Tris Cl pH 7.4 10 mM, NaCl 100
mM, EDTA 1 mM, EGTA 1 mM, Triton X 1 %, NaF 5
mM, Na3VO4 1 mM, PMSF 1 mM, leupeptin 10 μg/mL,
aprotinin 10 μg/mL, Roche tablet inhibitor) and the pro-
tein concentration was calculated by Bradford protein
assay reagent (Bio-Rad, USA). Proteins (50 μg) were sep-
arated by SDS-PAGE and transferred to nitrocellulosemembranes. After 1 h at room temperature in blocking
buffer (5 % nonfat milk in Tris-buffered saline/1 %
Tween 20 (TBS/T)) the membranes were washed three
times for 5 min each in TBS/T, and incubated overnight
at 4 °C with the primary antibodies: α-SMA, ET-1
(Abcam, USA), Col1A (Santa Cruz Biotechnology,
USA), Phospho-SMAD1/5, Phospho-SMAD2/3 (Cell
Signaling, USA) diluted in 5 % bovine serum albumin
in TBS/T. Following three washes with TBS/T, horse-
radish peroxidase-conjugated secondary antibodies
(Santa Cruz Biotechnology) diluted in blocking buffer
were added for 30 min at room temperature and
washed three times with TBS/T. The detection was per-
formed by enhanced chemiluminescence detection ECL
reaction (Amersham Pharmacia Biotechnology, USA).
All the results were normalized to the levels of proteins
of UT healthy control (HC) FBs and normalized to the
actin signal (Sigma-Aldrich). Immunoreactive bands
were quantified with densitometry using ImageJ soft-
ware (NIH, Bethesda, USA).
siRNA assay
In order to silence both ET-1 and ETAR expression,
SSc FBs were transfected with Silencer Select ET-1-
siRNA and ETAR-siRNA (Life Technologies) or with Si-
lencer Select Negative Control non-targeting siRNA
(scr) (Life Technologies) using Lipofectamine™ 3000
(Life Technologies, USA).
Transfection was performed according to the manu-
facturer’s instructions. Briefly, FBs were plated at 1 × 104
cells per cm2, 24 h prior to transfection. Cultures were
incubated for 24 h with 25 pmol siRNA in 2 mL Opti-
Mem. After incubation, plates were washed and cells
were allowed to recover in normal growth conditions
(10 % DMEM) for 24 h post-transfection.
Cipriani et al. Arthritis Research & Therapy  (2015) 17:247 Page 4 of 9Immunoprecipitation
Cells were washed three times with cold phosphate-
buffered saline and solubilized in 200 μl lysis RIPA buf-
fer (SDS 0.1 %, NP-40 1 %, Na3VO4 0.5 %, PMSF 1 mM,
aprotinin 10 μg/ml, Roche tablet inhibitor). After centri-
fugation at 12,000 rpm for 10 min, 0.5 mg protein was
subjected to immunoprecipitation. Specific anti-TβRI
antibody (Santa Cruz Biotechnology) was added and
rocked at 4 °C for 1 h; 30 μL protein A/G beads (Santa
Cruz Biotechnology) was added and the sample was
rocked over night at 4 °C. For Western blotting, anti-
Phosphoserine (BD Biosciences, CA, USA) and anti-
ETAR (Santa Cruz Biotechnology, USA) were used.
Statistical analysis
GraphPad Prism 5.0 software was used for statistical
analyses. Results are expressed as median (range). Due
to the nonparametric distribution of our data, the
Mann–Whitney U test was used as appropriate for ana-
lyses. Statistical significance was expressed by a p value
≤0.05.
Results
MAC inhibited the Col1A1 and α-SMA upregulation
induced by both TGF-β and ET-1
Figure 1 shows that under UT conditions the basal expres-
sion of Col1A1 and α-SMA protein was significantly
higher in SSc FBs when compared to HC FBs. The TGF-β
and ET-1 treatment induced a significant upregulation of
both Col1A1 and α-SMA expression when compared to
UT FBs, and this increase was significantly higher in SSc
FBs. MAC significantly blocked both TGF-β and ET-1 ef-
fects. The densitometry analysis of Western blot is re-
ported in Fig. 1.Fig. 1 Macitentan (MAC) inhibited both transforming growth factor beta (TG
gen 1 alpha 1 (Col1A1) and alpha smooth muscle actin (α-SMA) in fibroblasts
and α-SMA proteins was significantly higher in systemic sclerosis (SSc) FBs wh
induced a significant upregulation of both Col1A1 and α-SMA expression wh
FBs. MAC significantly blocked both TGF-β and ET-1 effects. Pictures are repre
etry and the values are expressed as protein relative quantification/β actin relTβRI activation in SSc FBs is blocked by MAC
Figure 2a shows that UT SSc FBs displayed an increased
SMAD1/5 and SMAD2/3 phosphorylation when com-
pared to UT HC FBs. TGF-β and ET-1 induced a sig-
nificant increase of both SMAD1/5 and SMAD2/3
phosphorylation in SSc and HC FBs. The level of phos-
phorylation was higher in SSc FBs. Although MAC is an
ET-1 antagonist, the Western blot showed that the drug
significantly inhibited both ET-1 and TGF-β effects. Fur-
thermore, we evaluated the phosphorylation of TβRI on
SSc FBs before and after TGF-β treatment, and our re-
sults show that MAC modulates the phosphorylation
level of TβRI, induced by TGF-β treatment (Fig. 2b).
SMAD phosphorylation is inhibited by MAC in SSc FBs
transfected with ET-1 siRNA
To inactivate ET-1 gene product in SSc FBs at a molecu-
lar level, we transfected SSc FBs with ET-1 siRNA or
scrambled control siRNA (scr-siRNA). ET-1 siRNA effi-
ciently (>70 %) knocked down ET-1. Figure 3a shows
that TGF-β stimulus induces a significant increase in
ET-1 expression in SSc FBs treated with scr-siRNA, but
in SSc FBs treated with ET-1 siRNA, TGF-β was unable
to induce an ET-1 increase. The Western blot analysis
confirmed the mRNA results (Fig. 3b).
In SSc FBs treated with scr-siRNA, TGF-β induced a
significant increase in SMAD phosphorylation, and
MAC inhibited this effect. Mirroring these data, MAC
inhibited the TGF-β effect also in SSc FBs treated with
ET-1 siRNA (Fig. 3b).
ETAR co-immunoprecipitates with TβRI
Although ETAR has been shown to heterodimerize with
other members of the ETR subfamily, heterodimerizationF-β) and endothelin-1 (ET-1) effects. Protein and gene expression of colla-
(FBs). Under untreated (UT) conditions the basal expression of Col1A1
en compared to healthy control (HC) FBs. The TGF-β and ET-1 treatment
en compared to UT FBs and this increase was significantly higher in SSc
sentative of all experiments. Protein bands were quantified by densitom-
ative quantification. **p = 0.0002, ***p = 0.0001
Fig. 2 Macitentan (MAC) blocked transforming growth factor beta type I receptor (TβRI) activation. a Protein expression of phospho-Sma and Mad
Related (pSMAD)1/5 and pSMAD2/3. Transforming growth factor beta (TGF-β) and endothelin-1 (ET-1) effects induced a significant increase of both
SMAD2/3 and SMAD1/5 phosphorylation. MAC significantly blocked both TGF-β and ET-1 effects. The phospho-SMAD levels were significantly higher
in systemic sclerosis (SSc) patients. Pictures are representative of all experiments. Protein bands were quantified by densitometry and the values are
expressed as protein relative quantification/β actin relative quantification. b TβRI was immunoprecipitated (IP) and its phosphorylation was assessed by
Western blot (WB). The immunoprecipitation assay showed a serine phosphorylation in TβRI after TGF-β treatment. MAC significantly inhibited the TβRI
phosphorylation. Immunoprecipitated protein bands were quantified by densitometry and the values are expressed as protein relative quantification/
TβRI relative quantification. **p = 0.0002, ***p = 0.0001. UT untreated
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found that the two receptors can be co-immunoprecipi-
tated from FBs in the absence of ligand. This association
was detected by immunoprecipitating the TβRI and
staining Western blots with ETAR (Fig. 4a). No further in-
crease in the amount of co-immunoprecipitating receptor
with the addition of other ligands, such as TGF-β or ET-1,
was observed. Of note, in SSc FBs, the ETAR levels that
co-immunoprecipitated were significantly higher, when
compared to HC FBs. These data parallel the evidence
that ETAR expression in SSc FBs was significantly higher
than ETAR expression in HC FBs (Fig. 4b).
SMAD phosphorylation is not blocked by MAC in SSc FBs
transfected with ETAR siRNA
To clarify the exact function of ETRs on the ETAR/TβRI
complex, we transfected the SSc FBs with ETRA siRNA or
scr-siRNA. In Fig. 4c, we show that, in ETAR-siRNA-
treated SSc FBs, a transient silencing of ETAR was observed
when compared to cells treated by negative scr-siRNA
(silencing >70 %). In SSc FBs treated with ETAR siRNA,pSMADs were significantly increased after TGF-β treat-
ment; of note, MAC lacks the ability to inhibit SMAD
phosphorylation, such as reported in SSc FBs transfected
with scr-siRNA (Fig. 4d).Discussion
Fibrosis of skin and internal organs is the dominant feature
of SSc and, to date, no therapy has been shown to revert
or arrest the progression of fibrosis. Myofibroblasts are
generally considered to be the major effector cells respon-
sible for the fibrotic events in the disease, since they con-
tribute to the increased synthesis and contraction of the
ECM, which is typical of this disorder. In fact, during SSc,
FBs may switch from a form that displays a quiescent
phenotype toward a proliferating, matrix-producing and
contractile phenotype. Although the origin of myofibro-
blasts is still a matter of debate, recent studies indicate that
bone marrow-derived mesenchymal progenitors undergo
myofibroblast differentiation in damaged tissues [24] and
we recently demonstrated that perivascular cells might
Fig. 3 Macitentan (MAC) effects in systemic sclerosis (SSc) fibroblasts (FBs) transfected with endothelin-1 (ET-1) siRNA. a SSc FBs were transfected with
specific ET-1 siRNA or nontargeting scramble scr-siRNA, and ET-1 expression was evaluated by quantitative RT-PCR. The cells transfected with ET-1 siRNA
showed a decreased expression of ET-1 gene, when compared with cells transfected with scr-siRNA. The transforming growth factor beta
(TGF-β) stimulus induces a significant increase in ET-1 expression in SSc FBs treated with scr-siRNA, but in SSc FBs treated with ET-1 siRNA;
TGF-β was unable to induce an ET-1 increase. b Western blot of phospho-Sma and Mad Related (pSMAD)1/5, pSMAD2/3 and ET-1 proteins. In
SSc FBs treated with scr-siRNA, TGF-β induced a significant increase in SMAD phosphorylation and MAC inhibited this effect. Mirroring these
data, MAC inhibited the TGF-β effect in SSc FBs treated with ET-1 siRNA. In SSc FBs transfected with ET-1 siRNA, ET-1 protein was not expressed.
Pictures are representative of all experiments. Protein bands were quantified by densitometry and the values are expressed as protein relative
quantification/β actin relative quantification. **p = 0.0002, ***p = 0.0001. UT untreated
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stimuli [5–7].
In the fibrotic process, TGF-β seems to play a pre-
eminent role [25–27]. This molecule exerts its action
through the induction (or repression) of many genes that
function as downstream targets and contribute to its ef-
fects in a coordinated way [28]. Its action is mediated by
SMAD family molecule phosphorylation and inhibiting
these downstream products blocks TGF-β effects [18]. It
has been reported that, in animal model of skin fibrosis,
TGF-β was able to induce transcriptional activation of
the ET-1 gene in dermal FBs [15], suggesting that these
cells possess an active TGF-β/ET-1 axis and both these
molecules may modulate fibrogenic responses. Further-
more, their synergistic effect seems to be particularly
complex and a co-operation between their own recep-
tors has been hypothesized.
Our results showed that, in skin FBs, ET-1, mirroring
the TGF-β behavior, was able to induce myofibroblast
activation, as shown by the increased expression of
ColA1 and α-SMA. Several reports [20, 29–31] showed
that ET-1 induces a profibrotic phenotype in FBs via the
increase of ECM protein expression and the decrease of
matrix metalloproteinase expression, suggesting that
blocking ET-1 signaling by bosentan, a dual ET-1 recep-
tor antagonist, could be a potential therapeutic strategyfor fibrotic disorders [29]. The main studies on the anti-
fibrotic effect of ETR antagonists on SSc FBs were re-
ported by Shi-Wen et al. [32–35], showing that bosentan
may suppress the expression of α-SMA, type I collagen,
fibronectin, and CCN2 in SSc lung FBs and that ET-1 acts
as a downstream mediator of TGF-β in human lung FBs.
Lagares et al. [15] repeated these results in dermal FBs
both in in-vitro experiments and in in-vivo animal models.
Recently, the ability of MAC to prevent the ET-1 profibro-
tic effects on SSc FBs has been demonstrated [20]. Thus,
ET-1 seems to be strongly involved in the fibrotic process,
and blocking its activity by specific receptor antagonists
may be helpful in the treatment of fibrotic disorders, al-
though the detailed molecular mechanism of action of
these new drugs still needs to be clarified.
In the present work, we showed that ET-1 performs its
action sharing the TGF-β signaling pathway. In fact ET-1
stimulation led to SMAD phosphorylation and MAC
blocking the ET-1-induced SMAD signaling pathway, pre-
venting the induction of myofibroblast markers. Further-
more, we showed that MAC may affect the ability of
TGF-β to induce TβRI phosphorylation. Of note, our data
show, for the first time, that MAC, which specifically
binds ETRs, also inhibits the ability of TGF-β to induce its
direct downstream signaling, resulting in reduced Col1A1
and α-SMA expression.
Fig. 4 Transforming growth factor beta type I receptor (TβRI)/endothelin-1 receptor A (ETAR) co-immunoprecipitation. a TβRI was immunoprecipitated
(IP) and its association with ETAR was assessed by Western blot (WB). The immunoprecipitation assay showed an association between ETAR and TβRI,
independent of both transforming growth factor beta (TGF-β) and endothelin-1 (ET-1) stimulation. In systemic sclerosis (SSc) fibroblasts (FBs), the levels
of co-immunoprecipitated receptors were significantly higher when compared with healthy control (HC) FBs. Blot was representative of all the
experiments. Co-immunoprecipitated protein bands were quantified by densitometry and the values are expressed as protein relative quantification/TβRI
relative quantification. b Western blot of ETAR protein. In SSc FBs, ETAR expression was significantly higher when compared with HC FBs. Blot was
representative of all the experiments. The protein bands were quantified by densitometry and the values are expressed as protein relative quantification/
β actin relative quantification. c SSc FBs were transfected with specific ETAR siRNA or nontargeting scramble scr-siRNA, and ETAR expression was
evaluated by quantitative RT-PCR. The cells transfected with ETAR siRNA showed a decreased expression of ETAR gene, when compared with cells
transfected with scr-siRNA. d Western blot of phospho-Sma and Mad Related (pSMAD)1/5 and pSMAD2/3. In SSc FBs treated with scr-siRNA, TGF-β
induced a significant increase in SMAD phosphorylation, and macitentan (MAC) inhibited this effect. In SSc FBs treated with ETAR siRNA, TGF-β induced
a significant increase in SMAD phosphorylation, and MAC failed to inhibit this effect. Pictures are representative of all experiments. Protein bands were
quantified by densitometry and the values were expressed as protein relative quantification/β actin relative quantification. **p = 0.0002, ***p = 0.0001.
UT untreated
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fect of MAC on TGF-β signaling is the evidence that
TGF-β is able to induce ET-1 production in FBs, and the
ability of TGF-β to induce myofibroblast markers is ET-1-
dependent [33]. In our experimental setting, MAC, by
blocking ET-1 induced after TGF-β stimulation, decreases
the expression of both collagen and contractile proteins.
To confirm that the MAC inhibitory effects on TGF-β
signaling are mediated by ET-1, we silenced the ET-1 gene
in SSc FBs. After silencing, we showed that MAC main-
tained its inhibiting action on SMAD phosphorylation re-
gardless of ET-1 production, leading us to speculate that
the ability of MAC to inhibit TGF-β signaling is independ-
ent of ET-1 production. Until some years ago, it was
thought that G protein-coupled receptors (GPCRs), likeETRs, and serine/threonine kinase receptors, such as TβRI,
along with their respective downstream effectors, repre-
sented distinct and linear signaling units that converged on
downstream targets. Recently, it has become more clear
that GPCR- and serine/threonine kinase receptor-mediated
signaling pathways are not mutually exclusive and they may
function as partners [36]. The GPCR–receptor tyrosine kin-
ase (RTK) partnerships may result from the activation of
RTKs in response to GPCR stimulation [37, 38], thus indu-
cing the formation of GPCR–RTK complexes.
This event has been already described in different bio-
logical settings: the platelet-derived growth factor recep-
tor, which is a member of the RTK family, may be found
in a tethered complex with the endothelial differenti-
ation gene 1, a member of the GPCR family [39], as well
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adrenergic receptors (GPCR family) which may form a
functional tethered complex [40, 41].
In our experimental setting, we observed a direct
interaction between the ET-1 and the TGF-β receptors,
which are members of different receptor families. This
interaction includes a physical association, as confirmed
by co-immunoprecipitation experiments. Of note, in SSc
FBs the co-immunoprecipitated levels were higher than
those observed in HC FBs, probably mirroring the evi-
dence that ETARs were significantly higher in SSc FBs.
After silencing ETAR, in SSc FB, MAC failed to inhibit
the SMAD phosphorylation induced by TGF-β treatment.
We may speculate that this TβRI–ETR complex mod-
ulates the effect of ET-1 on the TGF-β specific signaling
pathway, leading to the activation of a profibrotic pro-
gram in FBs. In this scenario, MAC binded in the pocket
of the ETR portion of the ET-1/TGF-β receptor complex
may induce a conformational change of this complex, re-
sponsible for the inhibition of TGF-β signaling. A fur-
ther speculative and unexplored aspect, in this setting,
may be blocking of the TβRI portion of the ET-1/TGF-β
receptor complex. However, until now, unlike ET-1, we
still do not have any licensed drug able to interfere with
TβRI [42], and from a clinical point of view, at present,
ET-1 receptor antagonists represent the only possibility
we have to modulate this functional complex.
The evidence of this heterogeneous, but functionally
active, TβRI–ETR complex suggests the possibility of an
antifibrotic effect of MAC, although these preclinical
findings need to be translated into the clinical setting. In
fact, although many in vitro studies suggested the antifi-
brotic effect of another ET-1 receptor antagonist, bosen-
tan [29, 32, 33], no clinical benefits were observed when
this drug was employed in SSc patients with lung fibro-
sis [43, 44]. It must be taken into account that the failure
of the clinical trials evaluating its efficacy on interstitial
lung disease may be biased by the choice of no sensitive
primary endpoint, as well as the heterogeneity of the en-
rolled patients and the lack of histological classifications.
On these bases, any further study of ET-1 receptor an-
tagonists in patients with fibrosis might need more strin-
gent inclusion criteria and perhaps use primary and
secondary endpoints which might be more responsive to
change [45].Conclusion
The present study provides the first demonstration, to our
knowledge, that some profibrotic effects of ET-1 may res-
ide on a physical coupling of its own receptor with the
TβRI, and MAC, binding with this hetero-receptor com-
plex, is able to block the TGF-β-induced signaling, inde-
pendently of the presence of ET-1.Our results allow us to speculate that, during SSc, ET-1,
accounting for vascular complications, may also contrib-
ute to the myofibroblast activation, via the TGF-β machin-
ery, thus linking the early endothelial damage to the
subsequent fibrotic process. The MAC inhibitory effect on
the TGF-β pathway, here reported, interfering with this
activation might suggest new therapeutic perspectives for
the treatment of fibrosis, a condition still needing specific
therapies.
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